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Abstract
Pathways producing and converting adenosine have hardly been investigated in human heart, contrasting work in other species. We 
compared the kinetics of enzymes associated with purine degradation and salvage in human and rat heart cytoplasm assaying for 
adenosine deaminase, nucleoside phosphorylase, xanthine oxidoreductase, AMP deaminase, AMP- and IMP-specific 5'-nucleotidases, 
adenosine kinase and hypoxanthine guanine phosphoribosyltransferase (HGPRT). Xanthine oxidoreductase was not detectable in human 
heart. The /Tm-values of the AMP-catabolizing enzymes were 2-5 times higher in human heart; the substrate affinity of the other 
enzymes was in the same order of magnitude in both species. The maximal activity (Vmax) of adenosine kinase was the same in both
species, but HGPRT in man was only 12% of that in the rat. For human heart the VLax-values of adenosine deaminase, nucleoside
phosphorylase, AMP- and IMP-specific 5'-nucleotidases, and AMP deaminase were 25-50% of those for rat heart. We conclude that 
human heart is less geared to purine catabolism than rat heart as is evident from the lower activities of the catabolic enzymes. 
Maintenance of the nucleotide pool may thus play a more important role in human heart.
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1. Introduction
Adenosine plays an important role in several cardio­
vascular processes. It is a potent vasodilator with depres­
sant effects on contractility, heart rate and conductance of
?
NP, AMP-D and HGPRT, have been investigated to a
lesser extent in human tissues (see footnote for abbrevia­
tions). Also the presence of two isozymes of 5'-NT differ­
ing in substrate preferences (AMP- and IMP-specific) found 
in various animal hearts [3] has not been confirmed in
%
the pacemaker nodes [1], The nucleoside may protect the human heart. Fig. 1 shows the pathways involved. Deacti-
heart by ‘preconditioning’ through A ,-receptor activation vation of adenosine is possible through rapid breakdown
[2]. The pathways that produce and catabolize adenosine in by ADA. This happens both inside and outside the cell [4];
hearts of several nonprimate,s have extensively been stud­
ied. In contrast, the activity and regulation of enzymes 
involved in purine-nucleotide metabolism, like AK, ADA,
Abbreviations: ADA: adenosine deaminase; AK: adenosine kinase; 
AMP-D: AMP deaminase; AOPCP: adenosine! a,/3-methylene)diphos- 
phate; DTT: dithiolhreitol; EHNA: erythro-9-(2-hydroxy-3-nonyl)adenine; 
HGPRT: hypoxanthine guanine phosphoribosyltransferase; NP: nucleo­
side phosphorylase; NSC 113939: 4-amino-5-iodo-7-( /3-d- 
riboiurano8yi)7H-pyiTolo[2,3-d]pyrimidine; 5'-NT: 5'-nucleotidase; PRPP: 
phosphoribosylpyrophosphate; SAH: S-adenosylhomocysteine; XOD: 
xanthine oxidoreductase
Hi
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the cellular process has been studied more thoroughly and 
is likely to be more important. ADA activity varies consid­
erably in hearts of different species [5]. Metabolic in­
hibitors for purine degradation, such as allopurinol and 
EHNA, are in use in cardioplegie solutions [6-8], as are 
adenosine catabolites like inosine to treat heart failure 
[9,10]. Those clinical trials assume the presence and activ­
ity of certain enzymes in the human heart. However, the 
enzymological background for such studies is absent.
The purpose of this study was to investigate the kinetics 
of cytosolic purine-metabolizing enzymes in human heart, 
with emphasis on the regulation of the adenosine level. 
This could give therapy and diagnostics with adenosine a
0304-4165/95/$09.50 © 1995 Elsevier Science B.V. All rights reserved 
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Fig. 1. Pathways of purine metabolism in rat and human heart. The 
conversions of hypoxanthine to xanthine and to urate catalyzed by XOD 
are probably absent in human heart. ADA, adenosine deaminase; AK, 
adenosine kinase; AMP-D, AMP deaminase; HGPRT, hypoxanthine gua­
nine phosphoribosyltransferase; NP, nucleoside phosphorylase; 5'-NT, 
5'-nucleotidase; SAHH, S-adenosylhomocysteine hydrolase; XOD, xan­
thine oxidoreductase.
better fundamental basis. We compared the human-heart 
data with those from rat heart, which is well described as a 
metabolic system.
2. Materials and methods
2,1, Human and rat myocardial homogenates
Human hearts were obtained from transplantation pa­
tients with end-stage heart failure (cardiomyopathy, hyper­
trophy, atherosclerosis, myocarditis etc.) of the Thoraxcen- 
ter, Erasmus University Rotterdam. The hearts were ar­
rested with cold St. Thomas’ Hospital cardioplegie solu­
tion, excised and cooled on ice; they arrived in the labora­
tory within 10 min. Nonfibrotic samples from the left- 
ventricular wall were cut into pieces. Some control experi­
ments ( n = 4) were done on healthy donor hearts, unused 
for transplantation for clinical reasons. Because the kinetic 
data obtained were comparable to the ones from explanted 
diseased hearts, the data were pooled. Hearts were also 
obtained from anesthetized male adult Wistar rats (250-270 
g) as described before [11]. For the AMP-D assay, 10% 
(w/v) homogenates were made in 20 mM Na+-dimethyl- 
glutarate (pH 7.4), 1 mM EDTA and 0.1 mM DTT. For 
HGPRT 20% (w/v) homogenates were made in 0.5 M 
Tris and 0.05 M MgCl2 (pH 7.4). The other assays were 
carried out in 5% (w/v) homogenates prepared as previ­
ously described [11]. The 5 and 10% homogenates were 
centrifuged (Sigma 2K15, Braun, Melsungen, Germany) 
for 5 min, at 12000 X g and 4°C, whereas the 20%
«
homogenate was centrifuged for 10 min, at 600 X g and 
4°C. To get rid of small molecules, PD-10 Sephadex 
columns (G-25M) were loaded with supernatant fluids and 
washed with buffer. Extracts were immediately used in the 
assays or stored at — 80° C.
The AK inhibitor NSC 113939 was a gift of the Na­
tional Cancer Institute (Bethesda, MD, USA). 5-Iodotu- 
bercidin (4-amino-5-iodo-7-( /3-D-ribofuranosyl)pyrrolo 
[2,3-d]pyrimidine), another AK inhibitor, was obtained 
from Research Biochemicals (Natick, MA, USA). The 
ADA inhibitor pentostatin (2'-deoxycoformycin, i.e., R-3- 
(2-deoxy-/3-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro[4, 
5-d][l,3]diazapin-8-ol) was from Parke-Davis (Detroit, MI, 
USA). EHNA, an alternative ADA inhibitor, was a gift 
from Wellcome Research Laboratories (Beckenham, Kent, 
UK). AOPCP, a potent membrane 5'-NT inhibitor, was 
bought from Sigma (St. Louis, MO, USA).
2.3. Determination of enzyme kinetics
Assays were carried out at 30° C. The half-saturation 
constant (Km) and the maximal activity (Vmax) were deter­
mined, using Lineweaver-Burk linearization of the 
Michaelis-Menten equation [12]. One unit is 1 /¿mol sub­
strate converted in one min or 1 ¿¿mol product formed in 
one min at 30° C. Values are presented as the mean ± S.E.
The activity of AK was measured with the radiometric 
method described by De Jong et al. [13]. There was no 
difference in results obtained with fresh and frozen (for 
< 2 days) supernatant fluids. The incubation mixture con­
tained 40 mM potassium phosphate (pH 7.0), 1.0 mM 
GTP-lithium salt, 1.0 mM MgCl2, bovine serum albumin 
0.05 mg/ml, and [U-I4C]adenosine (0.2-10 /¿M). After 
10 min incubations were stopped by distribution of aliquots 
from the reaction mixture on squares of DEAE-cellulose 
(Whatman DE81 ) to bind the reaction product, [ 14-C]AMP. 
The squares were washed with 1 mM ammonium formate, 
water and ethanol.
ADA activity was determined spectrophotometrically 
(Hitachi U-2000 double-beam) at 265 nm according to 
Coddington [14], During 5 min incubations the conversion 
of adenosine to inosine was measured in 50 mM potassium 
phosphate buffer (pH 7.4) with substrate concentrations 
between 2 and 100 ju.M.
The NP activity was analyzed spectrophotometrically 
(Hitachi U-2000 double-beam) at 293 nm during 5 min 
based on the method of Coddington [15] with modifica­
tions. Present were 0.1 M Tris (pH 7.4), xanthine oxidase 
0.1 U/ml, and either various concentrations of KH2P04 
(0.1-50 mM) with 0.3 mM inosine, or various concentra­
tions of inosine (0.02-1.0 mM) with 0.1 M K+-phosphate 
buffer (pH 7.4).
The incubation mixture for the HGPRT determination 
contained 0.4 mM hypoxanthine, 0.5 M Tris/0.05 M 
MgCl2 (pH7.4), 8 mM PRPP and 10% Triton X-100 in the 
ratio 10:10 ; 10:1. The reaction was started by adding 10 
/¿I supernatant fluid to 50 /¿I incubation mixture. After 
120 min at 30° C the reaction was stopped with HC104 (0.4 
M final concentration). Samples were kept on ice for 10
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min and centrifuged for 4 min, 15 000 X g at 4° C. K.HPO, 
was added to 50 ¡jl\ supernatant fluid in a final concentra­
tion of 0.14 M. The samples were analyzed on HPLC as
described previously [16].
For AMP-D determination Moss’ method [17] modified 
by Meghji et al. [5] was used. The reaction mixture 
contained 20 mM sodium dimethylglutarate (pH 7.0), 1 
mM EDTA, 0.1 mM dithiothreitol, 0.15 M KC1, 1 /xM 
EHNA, 1 mM ATP, and AMP in the range 0.5—15 mM. 
The reaction was stopped with 50% HC104 after 20 min. 
After centrifugation for 5 min at 4° C, 15000 X g, super­
natant fluids were taken and neutralized with 1.2 M 
K 2C03/30 mM EDTA. After centrifugation the super­
natant fluid was taken to estimate ammonia spectrophoto­
metrically at 625 nm according to Chaney and Marbach 
[18].
5'-NT was determined at 37° C as described by 
Skladanowski et al. [19]. The assay is based on the method 
of Newby [20] with some modifications for 5'-nucleoti- 
dases of different specificity [21]. For both assays the 
conditions adopted secured lack of cross reactivity of the 
two forms. Briefly, the final concentrations in the incuba­
tion mixture for the AMP-specific form of 5'-NT were: 
100 mM TES (or Hepes)/NaOH, pH 7.0, 10 mM MgCl2, 
30 mM NaCl, 1 mM ADP and AMP between 0.5-20 mM. 
To prevent conversion of adenosine to AMP and/or ino­
sine, 2 ¡llM 5-iodotubercidin and 10 ;uM EHNA were 
included. The reaction was stopped with 50 fil 1.3 M 
HCIO4 after 1.5 to 3 min. Samples were kept on ice for 30 
min, deproteinized, centrifuged and analyzed with HPLC 
[22]. The incubation conditions for the IMP-specific form 
of 5'-NT were: 100 mM imidazole/HCl, pH 6.5, 50 mM 
MgCl 2, 500 mM NaCl, 2.5 mM IMP and 2.5 mM ATP. 
The time course was linear for both assays. We recalcu­
lated the results from the earlier study [19] for 30° C, using
factors of 0.75 for human and 0.71 for rat AMP- and 
IMP-preferred 5'-NT, which we determined experimen­
tally .
3. Results and discussion
3.1. Adenosine kinase
Use of the AK inhibitors NSC 113939 (50 ¿¿M) and 
5-iodotubercidin (5 /¿M), proved that our AK measure­
ments were specific; they inhibited the reaction almost 
completely (94% and 96%, respectively). Inclusion of the 
ADA inhibitor pentostatin ( 1 /jlM )  in the reaction mixture 
did not change the Vmax, which shows that ADA did not 
interfere with the assay. Addition of AOPCP (50 /¿M), a 
potent membrane 5'-NT inhibitor [23], had no influence on 
the AK activity. We avoided thus possible product conver­
sion by ecto-5'-NT in the assay. The 1/max of AK in human 
myocardial homogenates was the same as in rat heart 
(Table 1). In both species, the ÆTm-values were in the low 
micromolar range (Table l). The observed species-dif- 
ferences are in line with those suggested earlier [25].
3.2. Adenosine deaminase
The inhibitor pentostatin (3 fiM) completely abolished 
ADA activity, showing that other reactions did not inter­
fere with our assay. In human heart the Vmax was about 
30% of that in rat heart (Table 1); however, the ATm-va]ues 
were almost identical (Table 1). Our results on ADA 
activity in human and rat heart agree with those published 
by Meghji et al. [5], although they made only one-point 
estimations. The kinetic data on rat heart are in line with 
Arch and Newsholme [26].
Table 1
Maximal activity ( x) and half-saturation constants (Km) of the adenylate-metabolizing enzymes (E) in rat and human hearts
Enzyme Substrate Vroax (mU/g wet weight) ( fiM)
Rat Human Rat Human
AK adenosine 38.9 ± 3.2 (3) 37.7 ± 0.8 (9) 2.30 ± 0.20 (3) 2.06 ±0.13 (9)
ADA adenosine 715 ±36 (3) 212 ± 17(11) 21.0 ±0.5 (3) 20.3 ±3.5 (11)
NP inosine 738 ± 52 (3) 245 ± 25 (8) 60.7 ± 8.6 (3) 62.1 ±4.8 (8)
P, 441 ± 26 (6) 134+ 12(5) 1540 ±100 (6) 2070 ± 570 (5)
XOD
1
xanthine 38.6+1.8 (5) “ < 1 4.5 ± 0.4 (5) a n.d.
hypoxanthine 38.1+4.3 (5)a < 1 3.0 ± 0.3 (5)a n.d.
HGPRT hypoxanthine 299 ± 44 (5) 36.0 + 2.6 (5) N.D. N.D.
AMP-D AMP 1837 ± 152(3) 976 + 20 (5) 1120 ± 130 (3) 2780 ± 180 (5)
5'-NT AMP 362 ± 17(3) 128 ±37 (6) 1220 ± 70 (3) 5320 + 570 (6)
IMP 533 ± 11 (5) 35 ± 9 (6) 20 ± 30 (5) 510 ±70 (6)
Enzyme assays were done on myocardial supernatant fluids. The activity of the catabolizing enzymes proved to be in human heart 12-50% of that in rat 
heart; the activity of adenosine kinase was the same in both species. In human heart the ifm-values were in the same order of magnitude as in rat heart, 
although they were at least twice higher for mononucleotide-catabolizing enzymes. Mean ± S.E. with number of experiments in parentheses. Por
abbreviations, see legend to Fig. 1. n.d., not detectable. N.D., not determined.
a Data from [24].
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3.3. Nucleoside phosphorylase a hyperbolic one. Our findings partly confirm other litera­
ture data on rat [32,33] and human heart [34],
In human myocardial tissue, the l/m,x of NP with ino­
sine or KH2P04 as variable substrate was about 30% of 
that in rat (Table 1). The Vnnx estimated with varying
inosine concentrations was about twice higher than with 
KH2P04 as variable substrate. This could be attributed to 
inhibition by the Tris-buffer used when phosphate was 
varied. The Km, however, was similar in both species 
(Table 1). We are unaware of kinetic data on human NP 
activity except for a qualitative estimation of activity in 
human and rat heart [27].
3.4. Xanthine oxidoreductase
Earlier our group could not detect XOD in
human-heart homogenate. We found a very low activity in 
perfused diseased human hearts [28], agreeing with the 
results of others [see, e.g., [29,30]]. In rat heart we deter­
mined activity [31] and kinetic data for XOD with hypox­
anthine and xanthine as substrate [24]. For both substrates 
the Vmax-values were the same; the ATni-values were in the 
lower micromolar range (Table 1).
3.5. Hypoxanthine guanine phosphoribosyltransferase
In human heart the Vmax of HGPRT with hypoxanthine 
as substrate was only 12% of the value for rat heart. Purine 
degradation, but also purine salvage to IMP via HGPRT, 
appears slow in human heart compared with rat heart.
3.6. AMP deaminase
Side reactions only interfered in rat heart at substrate 
concentrations higher than 15 mM by an arti factual sharp 
increase of ammonia production. The dependence of am­
monia production on AMP concentration was biphasic in 
rat- but not in human-heart homogenate. HPLC analysis of 
the postreactional mixtures revealed that the accelerated 
ammonia production at ^15  mM AMP correlated with 
formation of adenosine and inosine. Then the EHNA con­
centration (1 jjlM) seemed too low to inhibit ADA com­
pletely. At low concentrations of AMP, the production of 
adenosine, if detectable, was not accompanied by in­
creased inosine, showing effective inhibition of ADA. We 
decided to estimate activity values at substrate concentra­
tions < 10 mM. Then we observed a ynMIX for rat heart 
AMP-D twice higher than for human heart, where the 
delayed increase of ammonia did not take place (Table 1). 
The /¡Tm-values for AMP-D were similar in human and rat 
heart, i.e., in the lower millimolar range (Table 1). We 
found lower activities of AMP-D in both 
Meghji et al. [5]. This is presumably due to their overesti­
mation caused by EHNA’s incomplete inhibition of ADA 
at 25 mM AMP. The presence of 1 mM ATP in the 
AMP-D assay ensured that the sigmoidal curve turned into
3.7. 5'-Nucleotidase
In human heart the V¡nax of AMP- and IMP-preferred 
5'-NT was 25-30% of that in rat heart (Table 1). The 
/'¿'..-valúes for both substrates were 2-4 times higher in
human heart 1), a lower affinity of
5'-NT for AMP and IMP in man. Our results in rat heart 
were comparable with those from Truong et al. [35]. We 
found a 13-fold lower initial concentration of inosine 
accumulated in freshly prepared human-heart supernatant 
fluids compared to rat-heart ones. Concentrations were
= 7 ), res
lively. Additive effects of lower AMP dephosphorylation 
by 5'-NT and adenosine deamination by ADA in the 
human heart caused this difference with rat heart.
8.6 ± 1.2 p.M (n — 7) and 116 ± 3 pM (n
3.8. Physiological implications
One has to be cautious in the interpretation of the VLmax
of a particular reaction. We realize that we calculated 
kinetic values on enzymes present in cytosol, not on 
purified proteins. On the other hand, we avoided the 
instability problems sometimes seen with purified en­
zymes. In human myocardium the maximum velocities of 
the enzymes catabolizing adenylate to hypoxanthine 
(AMP-D, AMP- and IMP-specific 5'-NT, ADA and NP) 
were in a highly regular order 25-50% of those in rat 
heart. The V^nux of the anabolic enzyme AK was the same 
in both species, whereas the maximal HGPRT activity for 
human heart was only 12% of that observed for rat. We 
found the ATm-values of AK, ADA and NP to be either the 
same or in the same order of magnitude for both species. 
Thus we expect that the affinity of these enzymes to their 
substrates is similar. The /^„-values of AMP-D and 5'-NT
in human than in rat heart.(AMP/IMP) were 
suggesting a lower affinity of these two enzymes in human 
heart. Slower purine breakdown but not purine salvage via 
AK possibly protects the human heart at an earlier stage 
through purine accumulation instead of rapid breakdown to 
urate. Maintenance of the cardiac nucleotide pool may play 
a more important role in man than in rat.
A possible difference in tissue adenosine 
human and rat heart may be assessed by relating the flux 
rate determined from AMP to adenosine with the rate of 
adenosine degradation to inosine. From the data (Table I ) 
it appears that the lower V¡mix-value for 5'-nucleotidase in 
human heart is compensated by slower adenosine 
catabolism.
Borst et al. [36] determined kinetic values for SAH 
hydrolase in patients with hypertrophic obstructive car­
diomyopathy. Its activity is very low compared to the other 
enzyme activities involved in purine metabolism in human 
heart. We reoorted earlier that SAH hvdrolase activity does
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not contribute significantly to adenosine during ischemia, 
but could play a role during normoxia [37].
Our results give the maximal velocity obtainable and 
affinity toward substrates for the enzymes investigated. 
Free cytosolic AMP-concentrations in cardiomyocytes are 
probably in the submicromolar range even under ischemic 
conditions [38]. This is far below the Km of 5'-NT and 
AMP-D. We suggest that the rise in AMP-concentration 
due to hypoxia will give a large response in adenosine 
formation, reinforced by allosteric activation of 5'-NT. The 
next step is the rapid conversion to inosine by ADA (see 
Table 1).
The breakdown of inosine to hypoxanthine by NP de­
pends on the concentration of phosphate. Its physiological 
concentration in rat heart exceeds the 
NP by a factor of 1.5 [39]. When the free 
concentration rises (about three times) due to ischemia, the 
activity of NP might increase, approaching the Vmtlx-value. 
Thus, the intracellular phosphate concentration is possibly 
rate-limiting for adenosine degradation to hypoxanthine. 
We confirmed this in our AMP-specific 5'-NT assay: the 
amount of inosine present in the supernatant fluid 
chiometric with phosphate liberated from AMP 
converted to hypoxanthine by NP both in rat and human 
heart. Hypoxanthine salvage to IMP by HGPRT in human 
heart is possible but slow.
Km (phosphate) for
stoi
completely localized in the endothelial cells [44]; in rat 
heart we found this enzyme to be also present in the 
myocytes [11]. It is not known if the distribution of the 
enzymes discussed in this paper is the same in rat and 
human heart. We also did not deal with kinetics of nucleo­
side transport in cardiomyocytes and endothelial cells in 
this study. We only measured the kinetics of the enzymes 
involved in purine metabolism under optimal conditions in 
human and rat heart.
3.11. Conclusion
Human heart with its slower rate of adenosine forma­
tion from AMP, its lower activity of purine- 
enzymes and its virtual absence of XOD, is less geared to
and subsequent degradation than rat
heart.
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3.9. Cardiac IMP production
In skeletal muscle and liver, IMP produces inosine. 
There is consensus that in ischemic heart muscle like in 
brain, AMP degradation via adenosine is preferred. Olsson 
and Pearson suggested that the IMP pathway is dominant 
in cells generating ATP predominantly through anaerobic 
glycolysis; the adenosine pathway seems prominent in 
organs relying on oxidative phosphorylation [40], Our in 
vitro data would show that the capacity of the IMP path­
way exceeds the adenosine pathway in both species (see 
Table 1).
with •ane s activates
AMP-D [41]. Recently, Tanfani et al. suggested that syn­
chronized AMP-D inhibition by ATP decrease and this
association in heart shifts to
adenosine production by 5'-NT [41]. The cardioplegia-arre­
sted human heart produces considerable amounts of adeno­
sine besides inosine [42,43]. However, IMP accumulates in 
human heart as well [43].
3.10. Limitations of the study
We measured the of the in ho
mogenates, which consist of endothelial cells (ca. 4%) and 
cardiomyocytes. The localization of the enzymes in my-
•s in species. Forendothelial
example, nucleoside phosphorylase in guinea-pig heart is
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